HC Wainwright restated their buy rating on shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) in a report published on Wednesday morning, Benzinga reports. The firm currently has a $7.50 target price on the biopharmaceutical company’s stock.
Akebia Therapeutics Trading Down 3.0 %
NASDAQ AKBA opened at $1.59 on Wednesday. The company’s 50-day moving average price is $1.40 and its 200-day moving average price is $1.28. The stock has a market cap of $333.26 million, a PE ratio of -6.91 and a beta of 0.77. Akebia Therapeutics has a 12 month low of $0.78 and a 12 month high of $2.48.
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. The company had revenue of $43.65 million during the quarter, compared to the consensus estimate of $45.61 million. During the same quarter in the previous year, the company posted ($0.06) earnings per share. As a group, sell-side analysts forecast that Akebia Therapeutics will post -0.19 earnings per share for the current year.
Institutional Inflows and Outflows
About Akebia Therapeutics
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
Further Reading
- Five stocks we like better than Akebia Therapeutics
- ESG Stocks, What Investors Should Know
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- How to buy stock: A step-by-step guide for beginners
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- 5 discounted opportunities for dividend growth investors
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.